AVROBIO, Inc. (AVRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVRO Stock Price Chart Interactive Chart >
AVRO Price/Volume Stats
| Current price | $4.08 | 52-week high | $20.07 |
| Prev. close | $4.59 | 52-week low | $4.02 |
| Day low | $4.02 | Volume | 466,600 |
| Day high | $4.54 | Avg. volume | 465,796 |
| 50-day MA | $5.51 | Dividend yield | N/A |
| 200-day MA | $8.38 | Market Cap | 178.10M |
AVROBIO, Inc. (AVRO) Company Bio
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Latest AVRO News From Around the Web
Below are the latest news stories about AVROBIO Inc that investors may wish to consider to help them evaluate AVRO as an investment opportunity.
AVROBIO to Present at Two Upcoming Investor Conferences in NovemberCAMBRIDGE, Mass., November 09, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: |
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM ConferenceCAMBRIDGE, Mass., November 08, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher disease type 1 at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) on Nov. 21-23, 2021, in Sydney, Australia. |
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., November 05, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 120,000 shares of the company’s common stock to the company’s new Chief Medical Officer, Essra Ridha, M.D., as an inducement award under the company’s 2019 Inducement Plan. The grant was made in accordance with Nasdaq Lis |
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business UpdateCAMBRIDGE, Mass., November 04, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended Sept. 30, 2021, and provided a business update. |
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter SyndromeCAMBRIDGE, Mass., November 03, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-05, its lentiviral gene therapy for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome, a rare and seriously debilitating lysosomal disorder that primarily affects young boys. |
AVRO Price Returns
| 1-mo | -27.40% |
| 3-mo | -38.74% |
| 6-mo | -54.41% |
| 1-year | -70.92% |
| 3-year | -84.77% |
| 5-year | N/A |
| YTD | -70.73% |
| 2020 | -30.75% |
| 2019 | 20.90% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...